Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Absci (Nasdaq: ABSI) granted a 650,000-share non-statutory stock option to Dr. Ransi Somaratne as an inducement for his employment as Chief Medical Officer on March 3, 2026.

The option has a $2.57 exercise price (closing price on March 3, 2026), a 10-year term, and vests over four years (25% at one year, remainder in 36 monthly installments).

Key Figures

Inducement option size: 650,000 shares Exercise price: $2.57 per share Option term: 10 years +5 more

8 metrics

Inducement option size 650,000 shares Non-statutory stock option to CMO under 2023 Inducement Plan

Exercise price $2.57 per share Closing price on Nasdaq Global Select Market on Grant Date

Option term 10 years Maximum life of inducement stock option grant

Initial vesting tranche 25% Vests on one-year anniversary of March 3, 2026 Grant Date

Monthly vesting balance 75% over 36 months Remainder vests in approximately equal monthly installments

Full vesting period 4 years Option fully vested on fourth anniversary of Grant Date

Shelf registration amount $400,000,000 Maximum securities registered on Form S-3 shelf filed Aug 12, 2025

ATM component $100,000,000 Sales agreement prospectus with TD Securities (USA) LLC

Market Reality Check

Price: $2.59 Vol: Volume 3,247,586 is 1.16x...

normal vol

$2.59 Last Close

Volume Volume 3,247,586 is 1.16x the 20-day average of 2,801,881 shares. normal

Technical Shares at 2.59 are trading below the 200-day MA of 3.09 before this inducement news.

Peers on Argus

Peers show mixed moves: CGEM (-2.5%), INBX (-4.51%) down, while ATXS (+0.8%), LX...

Peers show mixed moves: CGEM (-2.5%), INBX (-4.51%) down, while ATXS (+0.8%), LXRX (+6.49%), and YMAB (+0.23%) are up, pointing to stock-specific rather than uniform sector trading.

Historical Context

5 past events · Latest: Mar 03 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 03	CMO appointment	Positive	-8.2%	New Chief Medical Officer named to lead AI-designed therapeutics.
Feb 24	Earnings date set	Neutral	+2.3%	Announces date for Q4 and full-year 2025 business update call.
Feb 17	Investor conferences	Positive	+4.3%	Participation in multiple March 2026 healthcare investor conferences.
Dec 16	JPM conference	Positive	+4.7%	Presentation at J.P. Morgan Healthcare Conference highlighting programs and platform.
Dec 11	Clinical data update	Positive	-3.3%	New human ex vivo data for ABS-201 on hair growth and stem cell niche.

Pattern Detected

Positive R&D and leadership updates have sometimes seen negative reactions, while investor-relations and conference announcements more often aligned with modest gains.

Recent Company History

Over the last few months, Absci’s news flow has centered on clinical advances, leadership changes, and investor outreach. A CMO appointment on Mar 3, 2026 coincided with a -8.21% move, while new human ex vivo data for ABS-201 on Dec 11, 2025 saw shares down 3.27%. In contrast, conference participation updates in Feb 2026 and the J.P. Morgan Healthcare Conference notice in Dec 2025 aligned with gains. Today’s inducement grant ties directly to the recent CMO hire within this leadership and clinical build-out narrative.

Regulatory & Risk Context

Active S-3 Shelf · $400,000,000

Shelf Active

Active S-3 Shelf Registration 2025-08-12

$400,000,000 registered capacity

An effective Form S-3 shelf filed on Aug 12, 2025 registers up to $400,000,000 of securities, including a $100,000,000 sales agreement prospectus with TD Securities (USA) LLC and carries forward $75,175,613 of unsold securities, providing pre-cleared capacity for future capital raises.

Market Pulse Summary

This announcement details a standard inducement equity grant of 650,000 option shares at a $2.57 exe...

Analysis

This announcement details a standard inducement equity grant of 650,000 option shares at a $2.57 exercise price to Absci’s new CMO, vesting over four years. It follows the earlier CMO appointment and adds to recent insider equity activity. Investors may track how leadership changes, future clinical readouts, and any use of the existing $400,000,000 shelf registration interact with compensation structures tied to long-term value creation.

Key Terms

non-statutory stock option, Nasdaq Listing Rule 5635(c)(4), exercise price

3 terms

non-statutory stock option financial

"the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares"

A non-statutory stock option is a company-granted right that lets a person buy shares later at a set price but does not receive special tax-favored treatment under tax law. It matters to investors because when the option is used the holder usually pays ordinary income tax on the gain and the company records compensation cost and issues new shares, which can reduce existing owners’ percentage ownership—think of it like a coupon to buy stock that creates a taxable event and some dilution.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

exercise price financial

"The stock option award has an exercise price of $2.57 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

AI-generated analysis. Not financial advice.

VANCOUVER, Wash. and NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced that on March 3, 2026, the company granted a non-statutory stock option to purchase an aggregate of 650,000 shares of its common stock to Dr. Ransi Somaratne in connection with his employment as Absci’s Chief Medical Officer. The inducement grant was previously approved by the Compensation Committee of Absci’s Board of Directors pursuant to Absci’s 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option award has an exercise price of $2.57 per share, the closing price of Absci’s common stock on the Nasdaq Global Select Market on March 3, 2026 (the “Grant Date”). The stock option award has a 10-year term and vests over four years, with 25% of the shares subject to the option vesting and exercisable on the one-year anniversary of the Grant Date while the remaining 75% of the shares vest and become exercisable in 36 approximately equal monthly installments thereafter such that the shares underlying the option granted to Dr. Somaratne will be fully vested on the fourth anniversary of the Grant Date, subject to Dr. Somaratne’s continued service with Absci on each such date (subject to the terms and conditions of the Inducement Plan and the option award agreement covering the grant).

About Absci

Absci is advancing the future of drug discovery with generative design to create better biologics for patients, faster. Our Integrated Drug Creation™ platform combines cutting-edge AI models with a synthetic biology data engine, enabling the rapid design of innovative therapeutics that address challenging therapeutic targets. Absci’s approach leverages a continuous feedback loop between advanced AI algorithms and wet lab validation. Each cycle refines our data and strengthens our models, facilitating rapid innovation and enhancing the precision of our therapeutic designs. Alongside collaborations with top pharmaceutical, biotech, tech, and academic leaders, Absci is advancing its own pipeline of AI designed therapeutics including ABS-201™, a groundbreaking innovation in hair regrowth with the potential to redefine treatment possibilities for androgenetic alopecia, commonly known as male and female pattern hair-loss. ABS-201 is also being investigated as a potential “best-in-class” therapeutic for endometriosis, a condition with significant unmet medical need and market potential. Absci is headquartered in Vancouver, WA, with AI Research Labs in New York City and Serbia, and an Innovation Center in Switzerland. Learn more at www.absci.com or follow us on LinkedIn (@absci), X (@Abscibio) and YouTube.

Absci^® standard character mark, ABS-201™, and Integrated Drug Creation™ are trademarks and registered trademarks of Absci Corporation.

Investor Contact
Alexander D.H. Khan
Corporate Vice President
Head of Investor Relations
investors@absci.com

Media Contact
press@absci.com

FAQ

What inducement did Absci (ABSI) grant to its new CMO on March 3, 2026?

Absci granted a non-statutory option for 650,000 shares as an inducement on March 3, 2026. According to the company, the award was approved under its 2023 Inducement Plan and is tied to Dr. Somaratne’s acceptance of employment.

What is the exercise price and term of the Absci (ABSI) stock option awarded to the CMO?

The option has an exercise price of $2.57 and a 10-year term. According to the company, $2.57 was the Nasdaq closing price on the March 3, 2026 grant date and the option expires ten years after grant.

How does the Absci (ABSI) option vest for Dr. Ransi Somaratne’s inducement grant?

The option vests over four years: 25% at one year, then the remaining 75% in 36 equal monthly installments. According to the company, full vesting occurs on the fourth anniversary, subject to continued service and plan terms.

Was the Absci (ABSI) inducement grant approved by the board or a committee?

The Compensation Committee approved the inducement grant under Absci’s 2023 Inducement Plan. According to the company, the committee acted pursuant to Nasdaq Listing Rule 5635(c)(4) for new-employee inducement awards.

Does the Absci (ABSI) inducement grant affect shareholder dilution immediately?

The grant itself does not cause immediate dilution; shares dilute only if options are exercised. According to the company, the award is an option to purchase 650,000 shares at $2.57, exercisable if vested and exercised by the holder.

What conditions govern the Absci (ABSI) inducement option becoming exercisable?

The option becomes exercisable as portions vest: 25% after one year and monthly thereafter, subject to continued service. According to the company, vesting and exercise are also governed by the Inducement Plan and the option award agreement.